Pharmacokinetic and pharmacodynamic analysis of 5-aza-2’-deoxycytidine (decitabine) in the design of its dose-schedule for cancer therapy
出版年份 2013 全文链接
标题
Pharmacokinetic and pharmacodynamic analysis of 5-aza-2’-deoxycytidine (decitabine) in the design of its dose-schedule for cancer therapy
作者
关键词
Decitabine, 5-aza-2’-deoxycytidine, Epigenetics, AML, MDS, DNA methylation, Pharmacokinetics, Pharmacodynamics
出版物
Clinical Epigenetics
Volume 5, Issue 1, Pages 3
出版商
Springer Nature
发表日期
2013-02-02
DOI
10.1186/1868-7083-5-3
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Transient Low Doses of DNA-Demethylating Agents Exert Durable Antitumor Effects on Hematological and Epithelial Tumor Cells
- (2012) Hsing-Chen Tsai et al. CANCER CELL
- Multicenter, Randomized, Open-Label, Phase III Trial of Decitabine Versus Patient Choice, With Physician Advice, of Either Supportive Care or Low-Dose Cytarabine for the Treatment of Older Patients With Newly Diagnosed Acute Myeloid Leukemia
- (2012) Hagop M. Kantarjian et al. JOURNAL OF CLINICAL ONCOLOGY
- Synergistic antileukemic action of a combination of inhibitors of DNA methylation and histone methylation
- (2012) Richard L. Momparler et al. LEUKEMIA RESEARCH
- p53-Independent, Normal Stem Cell Sparing Epigenetic Differentiation Therapy for Myeloid and Other Malignancies
- (2012) Yogen Saunthararajah et al. SEMINARS IN ONCOLOGY
- Effects of tetrahydrouridine on pharmacokinetics and pharmacodynamics of oral decitabine
- (2011) D. Lavelle et al. BLOOD
- Noncytotoxic Differentiation Treatment of Renal Cell Cancer
- (2011) Soledad Negrotto et al. CANCER RESEARCH
- A multicenter phase II trial of decitabine as first-line treatment for older patients with acute myeloid leukemia judged unfit for induction chemotherapy
- (2011) M. Lubbert et al. HAEMATOLOGICA
- Epigenetic regulation by decitabine of melanoma differentiation in vitro and in vivo
- (2011) Oscar Alcazar et al. INTERNATIONAL JOURNAL OF CANCER
- Low-Dose Decitabine Versus Best Supportive Care in Elderly Patients With Intermediate- or High-Risk Myelodysplastic Syndrome (MDS) Ineligible for Intensive Chemotherapy: Final Results of the Randomized Phase III Study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group
- (2011) Michael Lübbert et al. JOURNAL OF CLINICAL ONCOLOGY
- p53 Independent epigenetic-differentiation treatment in xenotransplant models of acute myeloid leukemia
- (2011) K P Ng et al. LEUKEMIA
- Recurrent DNMT3A mutations in patients with myelodysplastic syndromes
- (2011) M J Walter et al. LEUKEMIA
- DNMT3A mutations and response to the hypomethylating agent decitabine in acute myeloid leukemia
- (2011) K H Metzeler et al. LEUKEMIA
- Dnmt3a is essential for hematopoietic stem cell differentiation
- (2011) Grant A Challen et al. NATURE GENETICS
- Azacytidine and Decitabine Induce Gene-Specific and Non-Random DNA Demethylation in Human Cancer Cell Lines
- (2011) Sabine Hagemann et al. PLoS One
- Sustained exposure to the DNA demethylating agent, 2′-deoxy-5-azacytidine, leads to apoptotic cell death in chronic myeloid leukemia by promoting differentiation, senescence, and autophagy
- (2010) Michael Schnekenburger et al. BIOCHEMICAL PHARMACOLOGY
- Cancer Epigenetics
- (2010) Rodolphe Taby et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Vectorial Transport of Nucleoside Analogs from the Apical to the Basolateral Membrane in Double-Transfected Cells Expressing the Human Concentrative Nucleoside Transporter hCNT3 and the Export Pump ABCC4
- (2010) M. Rius et al. DRUG METABOLISM AND DISPOSITION
- Current and Future Management Options for Myelodysplastic Syndromes
- (2010) Jeffrey Bryan et al. DRUGS
- Azacytidine impairs NK cell reactivity while decitabine augments NK cell responsiveness toward stimulation
- (2010) Benjamin J. Schmiedel et al. INTERNATIONAL JOURNAL OF CANCER
- 3-Deazauridine enhances the antileukemic action of 5-aza-2′-deoxycytidine and targets drug-resistance due to deficiency in deoxycytidine kinase
- (2010) Noël J.-M. Raynal et al. LEUKEMIA RESEARCH
- Decitabine Maintains Hematopoietic Precursor Self-Renewal by Preventing Repression of Stem Cell Genes by a Differentiation-Inducing Stimulus
- (2010) Z. Hu et al. MOLECULAR CANCER THERAPEUTICS
- DNMT3AMutations in Acute Myeloid Leukemia
- (2010) Timothy J. Ley et al. NEW ENGLAND JOURNAL OF MEDICINE
- Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine
- (2010) W. Blum et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Effect of 5-Aza-2’-deoxycytidine on immune-associated proteins in exosomes from hepatoma
- (2010) Wen-Hua Xiao WORLD JOURNAL OF GASTROENTEROLOGY
- An operational definition of epigenetics
- (2009) S. L. Berger et al. GENES & DEVELOPMENT
- Frequent methylation of RASSF1A in synovial sarcoma and the anti-tumor effects of 5-aza-2′-deoxycytidine against synovial sarcoma cell lines
- (2009) Kunihiko Numoto et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Multicenter, Phase II Study of Decitabine for the First-Line Treatment of Older Patients With Acute Myeloid Leukemia
- (2009) Amanda F. Cashen et al. JOURNAL OF CLINICAL ONCOLOGY
- Importance of dose-schedule of 5-aza-2'-deoxycytidine for epigenetic therapy of cancer
- (2008) Maryse Lemaire et al. BMC CANCER
- Evolution of decitabine development
- (2008) Elias Jabbour et al. CANCER
- Inhibition of cytidine deaminase by zebularine enhances the antineoplastic action of 5-aza-2′-deoxycytidine
- (2008) Maryse Lemaire et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- The Expression and Clinical Significance of DNA Methyltransferase Proteins in Human Gastric Cancer
- (2008) Wen-Jin Ding et al. DIGESTIVE DISEASES AND SCIENCES
- Activity of decitabine in patients with myelodysplastic syndrome previously treated with azacitidine
- (2008) Gautam Borthakur et al. LEUKEMIA & LYMPHOMA
- Epigenetics in Cancer
- (2008) Manel Esteller NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy of decitabine in the treatment of patients with chronic myelomonocytic leukemia (CMML)
- (2007) P.W. Wijermans et al. LEUKEMIA RESEARCH
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started